Ignite Creation Date:
2024-05-06 @ 3:52 AM
Last Modification Date:
2024-10-26 @ 11:40 AM
Study NCT ID:
NCT02393794
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-04-27
First Post:
2015-03-13
Brief Title:
Cisplatin Plus Romidepsin Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer TNBC
Sponsor:
Priyanka Sharma
Organization:
University of Kansas Medical Center
Study Overview
Official Title:
Phase III Study of Cisplatin Plus Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation-Associated Locally Recurrent or Metastatic Breast Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study combination use of cisplatin plus romidepsin and nivolumab in metastatic triple negative breast cancer TNBC or BRCA mutation-associated locally recurrent or metastatic breast cancer
Detailed Description:
Breast cancer is the most common cancer and the second leading cause of cancer related death in American women Despite recent improvement in the treatment of breast cancer 40000 women per year still die in the USas a result of breast cancer Once the disease has gotten worse progressed after standard chemotherapy treatments there are limited treatment options and the likelihood for patients to recover is very small
The study will be done in two phases
Phase I will determine the highest dose of romidepsin that is safe and tolerable to take in combination with cisplatin
Phase II will determine if taking romidepsin at the dose determined in Phase I in combination with cisplatin and nivolumab is safe and effective in treating patients with breast cancer
Phase I will complete before Phase II begins
The study will be done in two phases
Phase I will determine the highest dose of romidepsin that is safe and tolerable to take in combination with cisplatin
Phase II will determine if taking romidepsin at the dose determined in Phase I in combination with cisplatin and nivolumab is safe and effective in treating patients with breast cancer
Phase I will complete before Phase II begins
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IIT-2014-PS-BRST-CISRomiTNBC | OTHER | University of Kansas Medical Center | None |
| RM-CL-BRST-PI-002783 | OTHER | None | None |